OS Therapies Incorporated (OSTX) AI Stock Analysis

• Market Cap: $63.03M
• Dividend Yield: N/A
• Average Volume (3M): 264.12K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.18
• Revenue Growth: N/A
• EPS Growth: -133.00%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 35,214,350
• 10 Day Avg. Volume: 191,474
• 30 Day Avg. Volume: 264,120
• PEG Ratio: -0.30
• Price to Book (P/B): -17.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.27
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -258.12
• Enterprise Value/Ebitda: -3.43
• 1Y Price Target: $11.50
• Price Target Upside: 528.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.69
• Revenue Forecast (FY): N/A

• Rating: 27 Underperform
• Price Target: ―

OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company's financial instability and negative market sentiment.

Positive Factors

Strong Liquidity

High cash reserves provide OS Therapies with the liquidity needed to fund R&D and operational expenses, supporting long-term growth and stability.

Improved Equity Position

A positive equity position indicates improved financial health, potentially due to capital injections or debt restructuring, enhancing future financing options.

Strategic Partnerships

Strategic partnerships can enhance market reach and provide additional revenue streams through milestone payments and royalties, supporting long-term growth.

Negative Factors

Negative Cash Flows

Persistent negative cash flows indicate ongoing operational challenges and reliance on external financing, which could threaten long-term sustainability if not addressed.

Lack of Revenue

The absence of revenue generation highlights difficulties in monetizing products, raising concerns about the company's ability to achieve profitability and sustain operations.

Increasing Net Losses

Rising net losses reflect challenges in cost management and revenue generation, potentially impacting the company's ability to invest in future growth and innovation.

OS Therapies Incorporated Business Overview & Revenue Model

Company Description

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

How the Company Makes Money

OS Therapies Incorporated generates revenue primarily through the commercialization of its proprietary therapies once they receive regulatory approval. The company engages in strategic partnerships and licensing agreements with larger pharmaceutical companies to co-develop and market its treatments, thereby earning revenue through upfront payments, milestone achievements, and royalties on sales. Additionally, OS Therapies may receive funding through grants and research collaborations with academic institutions and government agencies, which support its ongoing research and development efforts.

OS Therapies Incorporated Financial Statement Overview

Summary

OS Therapies Incorporated is experiencing significant financial challenges, characterized by a lack of revenue, increasing net losses, and negative operating cash flows. While there is a notable improvement in equity position and liquidity in 2024, the financial stability remains weak due to past leverage and ongoing operational losses. The company's reliance on external financing to sustain operations suggests potential risks if future fundraising efforts do not meet cash requirements.

Income Statement

OS Therapies Incorporated has reported no revenue for the past several years, indicating no income generation from operations. The company has consistently incurred significant net losses, with an increasing trend in net losses from -7.42 million USD in 2021 to -8.88 billion USD in 2024. This trend suggests a lack of profitability and potential challenges in revenue generation and cost management.

Balance Sheet

The company's balance sheet shows high cash reserves of 5.53 billion USD in 2024, indicating strong liquidity. However, the equity is negative in prior years, but significantly positive in 2024 at 6.05 billion USD, suggesting a recent capital injection or debt restructuring. The absence of total debt in 2024 improves the debt-to-equity ratio, though previous years show very high leverage with negative equity, indicating financial instability and potential risk in managing liabilities.

Cash Flow

Operating cash flows are consistently negative, reflecting ongoing cash usage in operations without any revenue inflow. The free cash flow has worsened from -3.79 million USD in 2022 to -7.28 billion USD in 2024, indicating increasing operational cash demands. Positive financing cash flow in 2024 suggests reliance on external financing to support cash needs, highlighting a potential risk if financing sources become restricted.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-239.54K	-2.78K	-4.22K	-805.00	-1.16M	-4.25K
EBITDA	-18.04M	-6.83M	-4.34M	-4.45M	-4.84M	-5.65K
Net Income	-18.28M	-8.88M	-7.79M	-6.25M	-7.42M	-6.03K
Balance Sheet
Total Assets	8.95M	5.54M	798.08K	509.11K	325.89K	1.68B
Cash, Cash Equivalents and Short-Term Investments	1.88M	5.53M	38.98K	171.48K	80.79K	1.23B
Total Debt	0.00	0.00	14.61M	10.35M	7.07M	6.77B
Total Liabilities	4.25M	4.73M	24.81M	18.07M	11.78M	8.00B
Stockholders Equity	4.71M	811.49K	-24.02M	-17.56M	-11.45M	-6.33B
Cash Flow
Free Cash Flow	-13.35M	-7.28M	-3.01M	-3.79M	-4.41M	-2.42B
Operating Cash Flow	-12.88M	-7.28M	-3.01M	-3.79M	-4.40M	-2.41B
Investing Cash Flow	-466.42K	0.00	1.15K	230.88K	200.47K	158.29M
Financing Cash Flow	13.37M	12.78M	2.87M	3.65M	3.05M	3.48B

OS Therapies Incorporated Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADVM	49 Neutral	$90.96M	-0.48	-417.79%	―	-100.00%	-42.12%
GANX	46 Neutral	$126.34M	―	-261.72%	―	―	42.29%
ATNM	41 Neutral	$42.11M	-1.03	-133.09%	―	11.11%	20.65%
ANVS	35 Underperform	$135.16M	―	-246.14%	―	―	62.84%
OSTX	27 Underperform	$63.03M	―	-914.04%	―	―	-133.00%